• Tuesday, November 9, 2021 @ 7:00 am

Versameb AG, a pre-clinical stage company focused on discovering and developing innovative RNA-based drugs,  announces that its CSO, Friedrich Metzger, presents data on its mRNA engineering technology and lead therapeutic candidate, VMB-100, under the title "Regeneration of muscle tissue and function in Stress Urinary Incontinence using engineered RNA" at the International mRNA Health Conference in Berlin.

  • VMB-100 shows therapeutic potential in Stress Urinary Incontinence
  • RNA engineering technology enhances the potency of mRNA

Versameb has developed a groundbreaking RNA technology platform, VERSagile, and is building a pipeline of promising first-in-class RNA therapeutics. VMB-100 has demonstrated first-in-class potential for treatment for Stress Urinary Incontinence (SUI) in a pre-clinical animal model showing regeneration and functional restoration of the urinary sphincter.  

Friedrich Metzger, Chief Scientific Officer, said: “Our findings indicate that local injection of our engineered mRNA results in therapeutically relevant target protein expression and secretion in muscle tissue, leading to muscle tissue regeneration. The regenerative effects seen following a single local injection support its therapeutic potential in muscle-related disorders such as stress urinary incontinence through restoration of muscle function.” 

Up to 50% of adult women suffer from SUI with no drug treatment currently approved. While behavioral and surgical interventions do exist, most are not effective in the long term.  

Klaas Zuideveld, Chief Executive Officer, said: “We are delighted to be presenting our findings at this prestigious conference. In the past year, the tremendous potential of mRNA has been shown through the COVID-19 vaccines. Versameb’s VERSagile platform has the potential to yield first-in-class RNA therapeutics for disease indications with high unmet need.” 

You may also be interested in